Oxazolidinone derivatives and methods of use
This invention relates to novel N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide derivatives, their acceptable acid addition salts, solvates and hydrates. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antimicrobial agents.
1. A compound of formula I or Ia:
or a pharmaceutically acceptable salt thereof, wherein:
each of W 1 , W 2 , W 3 , W 4 and W 5 is independently hydrogen or deuterium;
each of Y 1 , Y 2 , Y 3 and Y 4 is independently hydrogen or deuterium;
each of Z 1 , Z 2 , Z 3 and Z 4 is independently hydrogen, deuterium, or fluorine; and
at least one of W 1 , W 2 , W 3 , W 4 , W 5 is deuterium;
at least two of Y 1 , Y 2 , Y 3 and Y 4 are deuterium; and
at least two of Z 1 , Z 2 , Z 3 and Z 4 are deuterium or fluorine.
2. The compound of claim 1 , wherein W 1 and W 2 are simultaneously deuterium.
3. The compound of claim 1 , wherein W 1 and W 2 are simultaneously hydrogen, and no more than two of Z 1 , Z 2 , Z 3 and Z 4 are deuterium.
4. The compound of claim 1 , wherein Y 1 , Y 2 , Y 3 and Y 4 are simultaneously deuterium.
5. The compound of claim 1 , wherein each of Z 1 , Z 2 , Z 3 and Z 4 is independently selected from deuterium and fluorine.
6. The compound of claim 5 , wherein Z 1 , Z 2 , Z 3 and Z 4 are simultaneously deuterium.
7. The compound of claim 1 , wherein the configuration of the compound of Formula I or Ia is (S).
8. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 , wherein any atom not designated as deuterium is present at its natural isotopic abundance.
10. The compound of claim 8 , wherein any atom not designated as deuterium is present at its natural isotopic abundance.